secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001023024-23-000041
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharma Q3 revenue $131.8M (+57% YoY); raises FY2023 guidance
----------------------------------------------------------------

- Record Q3 net revenue $131.8M, up 57.3% YoY; GAAP net income $9.5M ($0.45 diluted EPS).
- Adjusted non-GAAP EBITDA $36.5M (+98% YoY); adj. diluted EPS $1.27 vs $0.58 YoY.
- Cortrophin Gel net sales $29.7M (+136% YoY); full-year Cortrophin guidance raised to $100M-$107M.
- FY2023 revenue guidance raised to $468M-$478M (prev. $425M-$445M); adj. EPS guided $4.29-$4.57.
- Generics/Established Brands revenue $102.1M (+43.4% YoY); 5 new products launched in Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000102302423000041/0001023024-23-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000102302423000041/ani-20231108.htm
  HTML page:      https://secwatch.observer/filing/0001023024-23-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer